- Home
- MKZR vs VIVS Comparison
MKZR vs VIVS Comparison
Compare MKZR & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKZR | VIVS |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 8.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MKZR | VIVS |
|---|---|---|
| Price | $4.72 | $2.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 48.9K | 37.8K |
| Earning Date | 02-11-2026 | 02-18-2026 |
| Dividend Yield | ★ 11.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,994,778.00 | $140,000.00 |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.63 | ★ 35.92 |
| 52 Week Low | $3.26 | $1.41 |
| 52 Week High | $31.80 | $21.96 |
Technical Indicators
Market Signals| Indicator | MKZR | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 62.04 | 55.55 |
| Support Level | $3.75 | $1.74 |
| Resistance Level | $4.72 | $2.10 |
| Average True Range (ATR) | 0.38 | 0.14 |
| MACD | 0.12 | 0.04 |
| Stochastic Oscillator | 100.00 | 83.56 |
Price Performance
Historical ComparisonAbout MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.